{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:29:03Z","timestamp":1790180943504,"version":"4.1.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1097\/cji.0b013e3181e311ac","type":"journal-article","created":{"date-parts":[[2010,6,15]],"date-time":"2010-06-15T07:25:29Z","timestamp":1276586729000},"page":"630-638","source":"Crossref","is-referenced-by-count":21,"title":["Immunogenicity for CD8+ and CD4+ T Cells of 2 Formulations of an Incomplete Freund's Adjuvant for Multipeptide Melanoma Vaccines"],"prefix":"10.1097","volume":"33","author":[{"given":"Craig L.","family":"Slingluff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina R.","family":"Petroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Smolkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"Chianese-Bullock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadedja","family":"Galeassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice Y.","family":"Neese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Grosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel J.","family":"Nail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrick","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"von Mehren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc E.","family":"Boisvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kirkwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210227","first-page":"647","article-title":"Montanide ISA 51 VG as Adjuvant for Human Vaccines","volume":"29","author":"Bonhoure","year":"2006","journal-title":"J Immunother"},{"key":"R2-8-20210227","first-page":"3012","article-title":"Phase I trial of a melanoma vaccine with gp100 (280\u2013288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes","volume":"7","author":"Slingluff","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R3-8-20210227","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.4049\/jimmunol.174.5.3080","article-title":"MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma","volume":"174","author":"Chianese-Bullock","year":"2005","journal-title":"J IImmunol"},{"key":"R4-8-20210227","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1245\/s10434-008-0046-4","article-title":"Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines","volume":"15","author":"Slingluff","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"R5-8-20210227","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1200\/JCO.2008.17.3161","article-title":"Helper T cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens","volume":"26","author":"Slingluff","year":"2008","journal-title":"J Clin Oncol"},{"key":"R6-8-20210227","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1158\/1078-0432.CCR-09-1544","article-title":"Effect of GM-CSF on circulating CD8+ and CD4+ T cell responses to a multipeptide melanoma vaccine: Outcome of a multicenter randomized trial","volume":"15","author":"Slingluff","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R7-8-20210227","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/CJI.0b013e31816dad10","article-title":"A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer","volume":"31","author":"Chianese-Bullock","year":"2008","journal-title":"J Immunother"},{"key":"R8-8-20210227","doi-asserted-by":"crossref","first-page":"6386","DOI":"10.1158\/1078-0432.CCR-07-0486","article-title":"Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting","volume":"13","author":"Slingluff","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R9-8-20210227","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1200\/JCO.2004.10.212","article-title":"Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule","volume":"22","author":"Slingluff","year":"2004","journal-title":"J Clin Oncol"},{"key":"R10-8-20210227","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1200\/JCO.2003.10.005","article-title":"Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells","volume":"21","author":"Slingluff","year":"2003","journal-title":"J Clin Oncol"},{"key":"R12-8-20210227","first-page":"976","article-title":"Effects of melanoma-derived helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine [abstract]","volume":"32","author":"Slingluff","year":"2009","journal-title":"J Immunother"},{"key":"R13-8-20210227","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00262-004-0592-y","article-title":"Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members","volume":"54","author":"Hogan","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"R14-8-20210227","first-page":"2099","article-title":"Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development [published erratum appears in J Immunol 1999;162:3106]","volume":"160","author":"Kittlesen","year":"1998","journal-title":"J Immunother"},{"key":"R15-8-20210227","first-page":"2539","article-title":"Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues","volume":"157","author":"Parkhurst","year":"1996","journal-title":"J Immunother"},{"key":"R17-8-20210227","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/01.cji.0000190399.98802.10","article-title":"Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines","volume":"29","author":"Rosenberg","year":"2006","journal-title":"J Immunother"},{"key":"R18-8-20210227","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.vaccine.2009.01.018","article-title":"Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies","volume":"27","author":"Chianese-Bullock","year":"2009","journal-title":"Vaccine"},{"key":"R19-8-20210227","first-page":"975","article-title":"The melanoma vaccine microenvironment: do negative contributors of immune function compartmentalize the vaccine site? [abstract]","volume":"32","author":"Schaefer","year":"2009","journal-title":"J Immunother"},{"key":"R20-8-20210227","first-page":"971","article-title":"Peptide\/incomplete Freund adjuvant emulsion depots are a graveyard for tumor antigen-specific CD8+ T cells [abstract]","volume":"32","author":"Overwijk","year":"2009","journal-title":"J Immunother"}],"container-title":["Journal of Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CJI.0b013e3181e311ac","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:31:12Z","timestamp":1786041072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002371-201007000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/cji.0b013e3181e311ac","relation":{},"ISSN":["1524-9557"],"issn-type":[{"value":"1524-9557","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}